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 MISMATCH REPAIR DEFICIENT TUMORS LACKING KNOWN SPORADIC CAUSES: 
ARE THEY ALL DUE TO LYNCH SYNDROME? 
Publication No. ______ 
Katherine Margaret Dempsey, B.A. 
Supervisory Professor: Dr. Karen Lu, M.D. 
BACKGROUND: Mismatch repair deficient (MMRD) colorectal (CRC) or endometrial (EC) cancers in 
the absence of MLH1 promoter hypermethylation and BRAF mutations are suggestive of Lynch 
syndrome (LS).  Positive germline genetic test results confirm LS.  It is unclear if individuals with 
MMRD tumors but no identified germline mutation or sporadic cause (MMRD+/germline-) have LS. 
HYPOTHESIS: Since LS is hereditary, individuals with LS should have a stronger family history of LS-
related cancers than individuals with sporadic tumors.  We hypothesized that MMRD+/germline- CRC 
and/or EC patients would have less suggestive family histories than LS CRC and/or EC patients.   
METHODS: 253 individuals with an MMRD CRC or EC who underwent genetic counseling at one 
institution were included in analysis in 1 of 4 groups: LS, MMRD+/germline-, MMRD+/VUS, sporadic 
MSI-H (MMRD tumor with MLH1 promoter hypermethylation or BRAF mutation).  Family histories 
were analyzed utilizing MMRpro and PREMM1,2,6.  Kruskal-Wallis tests were used to compare family 
history scores.  Logistic regression was used to determine what factors were predictive of LS. 
RESULTS:  MMRD+/germline- individuals had significantly lower median family history scores 
(PREMM1,2,6=7.3, MMRpro=8.1) than LS individuals (PREMM1,2,6=26.1, MMRpro=89.8, 
p<0.0001) and had significantly higher median family history scores than sporadic MSI-H 
(PREMM1,2,6 =5.0, p=0.0013, MMRpro=0.7, p<0.0001).  Family history scores were positively 
correlated with likelihood of testing germline positive (p<0.0001). 
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CONCLUSION: MMRD+/germline- individuals have less suggestive family histories of LS than 
individuals with LS, but more suggestive family histories than sporadic MSI-H individuals.  CRC and/or 
EC patients with abnormal tumor studies are more likely to have a germline LS mutation if they have a 
family history suggestive of hereditary cancer.  These results imply that the MMRD+/germline- group 
may not all have LS.  This finding highlights the need to determine other somatic, epigenetic or 
germline causes of MMRD tumors so that these patients and their families can be accurately counseled 
regarding screening and management. 
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INTRODUCTION 
Lynch syndrome (LS), also known as hereditary non-polyposis colorectal cancer (HNPCC), is 
an autosomal dominant hereditary cancer syndrome that confers a significantly increased lifetime risk of 
colorectal cancer (CRC) and endometrial cancer (EC) as well as an increased risk of a number of other 
cancers [1-5].  LS accounts for 2-4% of CRCs [6] and approximately 2% of ECs [7].  It is caused by 
germline mutations in the mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2, as well as 
EPCAM/TACSTD1 [8, 9].  The natural history of LS has been well established and screening and 
treatment guidelines have been created based on this natural history for affected individuals.   
Currently, the most effective way to identify individuals with possible LS is through tumor 
testing, which includes microsatellite instability (MSI) and immunohistochemistry (IHC).  
Approximately 95% of LS-related colorectal cancers are found to be MSI-high                                       
(MSI-H).  It is important to note that approximately 10-15% of sporadic CRCs [10, 11] and 20-30% of 
sporadic ECs [12] are also MSI-high. Loss of staining on IHC of one or more proteins is indicative of a 
somatic or germline defect in the MMR genes.  Tumors that exhibit high MSI and/or loss of staining on 
IHC are considered to be MMR deficient (MMRD).  A recent study out of MD Anderson Cancer Center 
in Houston, TX found that there was a 97% concordance rate between MSI and IHC testing [13].  
MMRD tumors can be indicative of a germline mutation and warrant further genetic counseling and 
testing.  MMRD tumors can also be due to epigenetic and somatic causes, such as MLH1 
hypermethylation or a BRAF V600E mutation, two well documented sporadic causes of MMRD tumors 
exhibiting high MSI and loss of MLH1 and PMS2 on IHC.  MLH1 hypermethylation or BRAF 
mutations are extremely rare in individuals with LS and the presence of either indicates the tumor is 
most likely sporadic [15].  Further tumor studies are necessary to rule out both these known sporadic 
causes in CRC.  MLH1 hypermethylation has been seen in ECs, but BRAF V600E mutations have not 
been implicated as a cause of sporadic MSI-high ECs [16].  
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The gold standard for diagnosing individuals with LS continues to be germline testing.  
Individuals with MMRD tumors should undergo comprehensive germline testing, including sequencing 
and deletion/duplication analysis of the appropriate MMR gene(s).  With positive germline testing, one 
can not only confirm a diagnosis of LS, but can also offer family members targeted mutation analysis.  
Germline testing has a specificity of greater than 99%, but has a low sensitivity ranging from 24% to 
67%, depending on genes implicated, type of germline testing used and population studied [7, 17, 18].   
As tumor studies have become more widespread, there is an emerging cohort of individuals who 
have MMRD tumors, but no identifiable mutation (MMRD+/germline-).  For example, in a recent study, 
23 of 59 patients (38.9%) with MMRD tumors who pursued genetic testing had uninformative negative 
genetic test results [19].  There are two possible explanations as to why this cohort has emerged: (1) 
these individuals do have LS, but our current genetic testing technology is not sensitive enough to detect 
the germline mutations in these individuals; or (2) these individuals do not have LS and there is another 
explanation for the phenotype of these individuals, such as epigenetic or somatic changes or modifier 
genes.  Other potential rare heritable causes of MMRD tumors include constitutional MLH1 
hypermethylation and complex rearrangements of the MMR genes that cannot currently be detected by 
germline testing technology [20].  In addition to MLH1 hypermethylation and BRAF V600E mutations, 
it has recently been discovered that, while rare, biallelic somatic mutations in the MMR genes are also 
possible [21, 22], as well as somatic mosaicism [22].     
 As this cohort has emerged, the question: “are all MMRD tumors due to Lynch syndrome?” has 
been raised by many.  The purpose of this study is to contribute to the answer to this overarching 
question by establishing if there is a difference between the family histories of LS individuals and the 
family histories of MMRD+/germline- individuals.  Because LS is hereditary, individuals with LS 
should, on average, have more family history of LS-related cancers than individuals with a sporadic 
CRC and/or EC.  A caveat to this assumption are families with MSH6 and PMS2 mutations.  Individuals 
with MSH6 and PMS2 mutations have lower lifetime risks of CRC and EC than individuals with MLH1 
and MSH2 mutations. They also tend to be diagnosed at a later age than individuals with MLH1 and 
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MSH2 mutations [17, 23].  We hypothesize that MMRD+/germline- CRC and/or EC patients have 
family histories that are less suggestive of LS than LS CRC and/or EC patients.   The specific aims of 
the project are as follows: (1) to assemble a cohort of individuals who have or have had CRC and/or EC 
and were treated at the University of Texas MD Anderson Cancer Center; (2) to utilize MMRpro and 
PREMM1,2,6 to quantify the family histories of these individuals; and (3) to examine the relationship 
between family history and germline testing results.  
MATERIALS AND METHODS 
Data collection 
The study sample included probands who presented to the University of Texas MD Anderson 
Cancer Center for genetic counseling for an MMRD CRC and/or EC from January 1995 to October 
2012.  Prior to 2009, individuals referred for genetic counseling had a suggestive family history or 
young age of diagnosis that raised suspicion for LS.  After 2009, reflex tumor studies for colorectal 
tumors began. After August 2012, reflex tumor studies for endometrial tumors began.  The vast majority 
of the study population, therefore, was considered high risk and is not a reflection of the general 
population.  Individuals were excluded if tumor study results, germline testing results or a pedigree were 
not available.  Individuals with tumor studies performed only on tissues other than colon or 
endometrium were excluded.  If multiple members of a family were seen for genetic counseling, only 
the individual who presented initially was analyzed.  Individuals who had a personal or family history 
indicative of another hereditary cancer syndrome were excluded. Individuals with tumors exhibiting low 
MSI and normal IHC who underwent germline testing were collected, but are not included in statistical 
analysis due to the lack of consensus that these tumor study results should be considered suggestive of 
LS and the lack of consistent referral of this patient population for genetic counseling and testing. The 
study protocol was approved by both the University of Texas Health Science Center at Houston on 
September 11, 2012 and the University of Texas MD Anderson Cancer Center on November 1, 2012. 
 Personal and tumor related information was collected for all probands.  Pedigrees for all 
probands were obtained from LOCUS, the Clinical Cancer Genetics MD Anderson database.   
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Risk Assessment Models 
Pedigree information was quantified by both PREMM1,2,6 (available from: http://dana-
farber.prod.dfcidev.org/pat/cancer/gastrointestinal/crc-calculator/default.asp) and MMRpro 5.1 
(available through University of Texas Southwestern’s CancerGene© version 5.1, available from: 
http://www4.utsouthwestern.edu/breasthealth/cagene/).  Both models are clinically validated risk 
assessment tools that provide the likelihood of identifying a germline mutation in one of the MMR 
genes (MLH1, MSH2, or MSH6) in the proband by taking into account personal and family history 
information.   
PREMM1,2,6 is based on a population of unrelated probands who submitted blood samples for 
MMR genetic testing.  PREMM1,2,6 will take into account the following factors for the proband: 
gender, personal history of CRC, personal history of EC, age of diagnosis of EC or CRC, and personal 
history of other LS-related tumor(s).  The model will also take into account the following factors for 
affected first- and second- degree relatives: number of individuals affected by CRC, number of 
individuals affected by EC, age of diagnosis of CRC or EC, and history of LS-related tumor(s) [24].  
LS-related tumors are considered to be: ovarian, gastric, small bowel, hepatobiliary, renal/urinary tract, 
pancreatic, glioblastoma multiforme, and sebaceous gland tumors.  PREMM1,2,6 uses a multivariate 
logistic regression to perform the risk analysis.  The most important factors for PREMM1,2,6 are: 
proband with personal history of CRC and family history of CRC; proband with personal history of 2 or 
more CRCs; and any individual (proband, first- or second-degree relative) with EC [24].  
MMRpro is based on theoretical modeling, not a specific study population.  It attempts to 
answer the following question: what is the probability the proband carries a mutation in one of the 
MMR genes given the pattern of affected individuals and unaffected individuals in the family?  
MMRpro will take into account the following information for the family, which consists of the proband, 
first-degree relatives and second-degree relatives: CRC and location (proximal, distal or unknown), EC, 
age of onset, age of all unaffected relatives, ancestry and ethnicity, results of MSI/IHC testing, results of 
germline testing, and carrier status of family members [25].  MMRpro utilizes Bayesian analysis with 
mutation frequency, penetrance estimates, and non-carrier incidence based on literature reviews [25].  
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If exact ages were not available, conservative estimation based on available information was 
utilized.  Individuals for whom limited information was available were excluded from pedigree analysis. 
Half-siblings were not used in pedigree analysis. While MMRpro can take results from tumor studies 
into account in the risk calculation, we chose not to use this in our risk assessment.  When results from 
tumor studies are included, they predominate in the calculated risk assessment, thus blunting the ability 
of the model to summarize the suggestiveness of the family history.  
Statistical Considerations 
Summary statistics were performed to analyze the demographic, clinical and genetic 
characteristics of the patients.  Chi-squared test, Fisher’s exact test, or Kruskal-Wallis test were 
conducted to compare demographic characteristics between germline testing groups and pairwise 
comparisons were performed to determine statistical significance between groups.  To control for 
multiple comparisons, a Bonferroni correction was used with alpha defined as 0.008.  A Kruskal-Wallis 
test was conducted to compare family history scores.  A Wilcoxon rank sum test was conducted to 
compare all pairwise comparisons.  To control for multiple comparisons, a Bonferroni correction was 
used for the pairwise comparisons where statistical significance was defined at the alpha = 0.008 level.  
Wilcoxon rank sum test were also conducted to compare germline testing groups by colon/endometrial, 
gender and age.  For these pairwise comparisons, a Bonferonni correction was used where statistical 
significance was defined at the alpha = 0. 01 level.  A logistic regression model was also conducted with 
a term for family history as a predictor to predict the odds of testing germline positive.  The model 
controlled for the following variables: age, gender, cancer type and ethnicity.  All analyses were 
performed using STATA/SE 12.1.  
RESULTS 
Demographics 
Information for 274 individuals who fell into one of four groups was collected: LS, 
MMRD+/germline-, variant of uncertain significance (MMRD+/VUS) and known sporadic (sporadic 
MSI-H), defined as tumors with the presence of MLH1 hypermethylation and/or BRAF V600E 
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mutation.  An additional 21 individuals with MSI-low and tumors with intact IHC were excluded (figure 
1). 
Demographic information for the final population (n=253) is summarized in table 1 by 
comparing the four groups.  Statistically significant differences between groups (alpha = 0.05) were 
identified for age at diagnosis (p=<0.0001), ethnicity (p=0.0402), type of cancer (p=0.0476) and 
additional polyps at time of cancer diagnosis (p=0.0034).  Overall, mean age of diagnosis was 51.5 
years (SD=13.2).  Our overall population was predominantly Caucasian (n=201, 79.8%).   
64.7% of the overall population (n=116) had no additional polyps at the time of diagnosis.  
 Average age of diagnosis for the LS group was 48.3 years (SD=12.6), younger than the 
sporadic MSI-H group (p<0.008).  Individuals in the LS group were more likely to have additional 
polyps at time of cancer diagnosis (47%) than the sporadic MSI-H group (p<0.008).  Average age of 
diagnosis for the MMRD+/germline- group was 51.3 years (SD=12.7), significantly younger than the 
sporadic MSI-H group (p<0.008).  Average age of diagnosis for the MMRD+/VUS group was 46.2 
years (SD=8.9), significantly younger than the sporadic MSI-H group (p<0.008).  Individuals in the 
MMRD+/VUS group were significantly less likely to have additional polyps at the time of diagnosis 
(9.1%) than the LS group (p<0.008).  The MMRD+/VUS group had significantly more ethnic diversity 
than the sporadic MSI-H group (p <0.008).  Average age of diagnosis for individuals in the sporadic 
MSI-H group was 60.5 years (SD=13.0, p <0.008), significantly older than the three other groups.  EC 
was more common in the sporadic MSI-H group (27.3%).  Average body mass index (BMI) of 
individuals with EC varied significantly between groups (p=0.0138).  Overall average BMI for the EC 
group was 28.8.  Individuals in the LS group on average had a BMI of 23.7, lower than the overall 
group and the three other groups. 
Tumor Characteristics 
Tumor characteristics for CRCs overall (n=211) and between groups (LS n=85; 
MMRD+/germline- n=58; MMRD+/VUS n=28; sporadic MSI-H n=40) are summarized in table 2. 
Statistical significance was reached for gender (p=0.0228).  Overall, there were 106 males with CRC  
   
Figure 1: 
Schema of 
Study 
Population 
Selection
Individuals 
excluded 
initially did 
not have 
pedigrees, 
germline 
testing results 
or tumor 
studies results 
available; were 
not the 
proband in 
their family; 
had tumor 
studies 
performed on 
tissues aside 
from CRC or 
EC, or had a 
history 
consistent with 
another 
genetic 
condition. 
Individuals 
excluded later 
had MSI
tumors with 
intact staining.
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  Germline Testing Group      
LS 
 (n = 97) 
MMRD+/ 
Lynch- 
(n = 70) 
MMRD+/VUS 
 (n = 31) 
sporadic MSI-H 
 (n = 55) 
Total  
(n = 253)  
  N % N % N % N % N 
 
%  p-value 
Age c, e, f          <0.0001 
N 97 70 31 55 253  
Mean (SD) 48.3 (12.6) 51.3 (12.7) 46.2 (8.9) 60.5 (13.0) 51.5 (13.2)  
Min (Med) Max 23 (48) 83 24 (50) 81 30 (46) 67 25 (60) 83 23 (50) 83  
Vital Status 0.5280 
Alive 79 81.4 62 88.6 28 90.3 48 87.3 217 85.8  
Deceased 18 18.6 8 11.4 3 9.7 7 12.7 36 14.2  
Ethnicity f 0.0402 
Caucasian 77 80.2 57 81.4 18 58.1 49 89.1 201 79.8  
African American 6 6.3 4 5.7 4 12.9 1 1.8 15 6.0  
Hispanic 9 9.4 6 8.6 2 6.5 2 3.6 19 7.5  
Asian 3 3.1 3 4.3 6 19.4 3 5.5 15 6.0  
Other 1 1.0 0 0.0 1 3.2 0 0.0 2 0.8  
Tumor Location 0.0476 
Colon 80 82.5 58 82.9 28 90.3 40 72.7 206 81.4  
Endometrial 12 12.4 12 17.1 3 9.7 15 27.3 42 16.6  
Both 5 5.2 0 0.0 0 0.0 0 0.0 5 2.0  
Additional Polyps in Colon b 0.0034 
No 35 53.0 35 76.1 20 90.9 26 68.4 116 67.4  
Yes 31 47.0 11 23.9 2 9.1 12 31.6 56 32.6  
Other Cancer  0.1498 
No 50 51.5 47 67.1 20 64.5 36 65.5 153 60.5  
Yes 47 48.5 23 32.9 11 35.5 19 34.5 100 39.5  
Number of other cancers  
0 50 51.5 47 67.1 20 64.5 36 65.5 153 60.5  
1 26 26.8 16 22.9 9 29.0 12 21.8 63 24.9  
2 10 10.3 5 7.1 1 3.2 3 5.5 19 7.5  
3 5 5.2 0 0.0 0 0.0 2 3.6 7 2.8  
4 3 3.1 1 1.4 1 3.2 1 1.8 6 2.4  
5 2 2.1 0 0.0 0 0.0 1 1.8 3 1.2  
7 0 0.0 1 1.4 0 0.0 0 0.0 1 0.4  
8 1 1.0 0 0.0 0 0.0 0 0.0 1 0.4  
Significant pairwise comparisons (alpha < 0.008):  a LS vs. MMRD+/germline-;   b LS 
vs. MMRD+/VUS;  c LS vs. Sporadic MSI-H;  d MMRD+/germline- vs. 
MMRD+/VUS;   e MMRD+/germline- vs Sporadic MSI-H;  f MMRD+/VUS vs. 
sporadic MSI-H                         
Table 1: Demographic Information 
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  Germline Testing Group      
LS 
 (n = 85) 
MMRD+/ 
germline-  
(n = 58) 
MMRD+/VUS 
 (n = 28) 
sporadic  
MSI-H 
 (n = 40) 
Total  
(n = 211) 
 
  N % N % N % N % N % p-value 
Gender            
          Male 47 58.8 28 48.3 18 64.3 13 32.5 106 51.5 0.0228 
          Female 33 41.3 30 51.3 10 35.7 27 67.5 100 48.5  
Location --+ 
   Ascending 38 44.7 31 53.4 16 57.1 25 62.5 110 52.1  
   Transverse 16 18.8 11 19.0 4 14.3 12 30.0 43 20.4  
   Descending 12 14.1 6 10.3 4 14.3 3 7.5 25 11.8  
   Rectum 19 22.4 10 17.2 4 14.3 0 0.0 33 15.6  
Histology >0.9999 
Adenocarcinoma 84 98.8 58 100.0 28 100.0 40 100.0 210 99.5  
Tubular adenoma 1 1.2 0 0.0 0 0.0 0 0.0 1 0.5  
Grade           0.6595 
1 4 4.9 2 3.6 0 0.0 2 5.0 8 3.9  
2 57 69.5 38 67.9 20 71.4 22 55.0 137 66.5  
3 21 25.6 16 28.6 8 28.6 16 40.0 61 29.6  
Stage --+ 
I 23 29.1 7 12.3 3 10.7 3 7.9 36 17.8  
II 26 32.9 21 36.8 11 39.3 14 36.8 72 35.6  
III 19 24.1 18 31.6 9 32.1 13 34.2 59 29.2  
IV 11 13.9 11 19.3 5 17.9 8 21.1 35 17.3  
IHC           --+ 
MLH1&PMS2* 20 25.3 34 61.8 14 50.0 39 100.0 107 53.2  
MSH2 & MSH6* 38 48.1 10 18.1 8 28.6 0 0.0 56 27.9  
PMS2 6 7.6 3 5.5 2 7.1 0 0.0 11 5.5  
MSH6 12 15.2 5 9.1 2 7.1 0 0.0 19 9.5  
No loss staining 3 3.8 3 5.5 2 7.1 0 0.0 8 4.0  
MSI 0.0560 
High 67 100.0 40 90.9 23 95.8 33 97.1 163 96.4  
Low 0 0.0 1 2.3 0 0.0 1 2.9 2 1.2  
MSS 0 0.0 3 6.8 1 4.2 0 0.0 4 2.4  
*There were 21 individuals overall (5 LS, 9 MMRD+/germline-, 1 MMRD+/VUS and 6 sporadic MSI-
H) who had staining for MLH1 alone and 1 individual overall (MMRD+/germline-) who had staining 
for MSH2 alone before staining for PMS2 and MSH6 was available.  These individuals were 
incorporated into the statistics for MLH1&PMS2 and MSH2&MSH6, as they would likely have stained 
negative for PMS2 and MSH6 if it had been available.  
+ Statistical significance could not be established, as numerous individuals were missing this 
demographic characteristic 
Table 2: Colorectal Cancer Characteristics 
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(51.5%) and 100 females with CRC (48.5%).  In general, the sporadic MSI-H group had more females 
(67.5%) and the MMRD+/VUS group had more males (64.3%).  Location, histology, grade and MSI 
results were similar among all groups.  Overall, the majority of tumors were either stage II (35.6%) or 
stage III (29.2%).  Individuals in the LS group were more likely to have a stage I tumor (29.1%).  
Overall, most tumors exhibited loss of MLH1 and PMS2 (n=86, 42.8%) followed by loss of MSH2 and 
MSH6 (27.4%) on IHC.  In the positive group, there were more tumors with loss of MSH2 and MSH6 
(48.1%) and MSH6 only (15.2%) on IHC staining than the overall population.   
Tumor characteristics for ECs overall (n=47) and between groups (LS n=17; 
MMRD+/germline- n=12; MMRD+/VUS n=3, sporadic MSI-H n=15) are summarized in table 3.  
Location and IHC results were significantly different between groups (p=0.0407 and p=0.002 
respectively).  Overall, the majority of tumors were located in the uterine body (78.7%).  100% of 
sporadic MSI-H tumors were located in the uterine body.  Overall, IHC revealed loss of MLH1 and 
PMS2 in 23 tumors (48.9%) and loss of MSH2 and MSH6 in 16 tumors (34.0%).  In general, the LS 
group had more tumors with loss of MSH2 and MSH6 (58.8%) and MSH6 only (11.8%).  As expected, 
the sporadic MSI-H group had significantly more individuals with loss of MLH1/PMS2 on IHC (100%) 
than the other groups (p<0.008).  Histology, grade, stage and MSI results were similar among all 
groups.    
Germline Testing 
As expected, germline test results and IHC results were concordant for both the LS group and 
the MMRD+/VUS group.  46.4% (n=45) of LS individuals overall had a germline MSH2 mutation.  
48.1% (n=38) of LS CRC individuals had loss of MSH2 and MSH6 on IHC and 43.8% (n=35) had 
germline MSH2 mutations identified.  58.8% (n=10) of LS EC patients had loss of MSH2 and MSH6 on 
IHC and 66.7% (n=8) had germline MSH2 mutations identified.  40% (n=2) of women who had both 
CRC and EC had MSH2 mutations.  The two most common genes in which MMRD+/VUS were 
identified were MLH1 (n=16, 50%) and MSH2 (n=12, 37.5%).  50% (n=14) of MMRD+/VUS CRC)  
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  Germline Testing Group      
LS 
 (n = 17) 
MMRD+/ 
germline- 
(n = 12) 
MMRD+/VUS 
 (n = 3) 
sporadic  
MSI-H 
 (n = 15) 
Total  
(n = 47)  
  N % N % N % N % N % 
p-
value 
Location 0.0407 
Lower Uterine  6 35.3 3 25.0 1 33.3 0 0.0 10 21.3  
Uterine Body  11 64.7 9 75.0 2 66.7 15 100.0 37 78.7  
Histology 0.1112 
Endometrioid 14 82.4 10 83.3 2 66.7 14 93.3 40 85.1  
Serous 1 5.9 0 0.0 0 0.0 0 0.0 1 2.1  
Mixed high  2 11.8 0 0.0 0 0.0 1 6.7 3 6.4  
Clear cell 0 0.0 2 16.7 0 0.0 0 0.0 2 4.3  
Papillary 0 0.0 0 0.0 1 33.3 0 0.0 1 2.1  
Grade 0.9867 
1 3 20.0 2 18.2 0 0.0 2 13.3 7 16.3  
2 9 60.0 7 63.6 2 100.0 11 73.3 29 67.4  
3 3 20.0 2 18.2 0 0.0 2 13.3 7 16.3  
Stage  0.2890 
I 7 53.8 5 55.6 0 0.0 8 61.5 20 52.6  
II 2 15.4 0 0.0 2 66.7 2 15.4 6 15.8  
III 3 23.1 4 44.4 1 33.3 2 15.4 10 26.3  
IV 1 7.7 0 0.0 0 0.0 1 7.7 2 5.3  
IHC c 0.0002 
MLH1&PMS2* 3 17.6 7 58.3 1 33.3 15 100.0 26 55.3  
MSH2 & MSH6* 10 58.8 4 33.3 2 66.7 0 0.0 16 34.0  
PMS2 1 5.9 0 0.0 0 0.0 0 0.0 1 2.1  
MSH6 2 11.8 0 0.0 0 0.0 0 0.0 2 4.3  
No loss staining 1 5.9 1 8.3 0 0.0 0 0.0 2 4.3  
MSI 0.8603 
High 9 90.0 8 88.9 3 100.0 11 91.7 31 91.2  
Low 1 10.0 0 0.0 0 0.0 1 8.3 2 5.9  
MSS 0 0.0 1 11.1 0 0.0 0 0.0 1 2.9  
*There were 3 individuals overall (1 LS, 1 MMRD+/germline-, 1 sporadic MSI-H) who had staining 
performed for MLH1 only before staining for PMS2 was available.  These individuals have been added 
to the statistics for MLH1&PMS2, as they likely would have stained negative for PMS2 if it had been 
available.  
Significant pairwise comparisons (alpha < 0.008):  a LS vs. MMRD+/germline-;   b LS vs. 
MMRD+/VUS;  c LS vs. Sporadic MSI-H; d MMRD+/germline- vs. MMRD+/VUS;   e 
MMRD+/germline- vs Sporadic MSI-H;  f MMRD+/VUS vs. Sporadic MSI-H 
Table 3: Endometrial Cancer Characteristics 
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Table 4: Family History Assessment Summary Statistics 
individuals had loss of MLH1 and PMS2 on IHC and 55.2% (n=16) had a MMRD+/VUS in MLH1.  
28.6% (n=8) had loss of MSH2 and MSH6 on IHC and 31% (n=9) had a MMRD+/VUS in MSH2.  No 
EC MMRD+/VUS individuals had a MMRD+/VUS in MLH1.  66.7% (n=2) had loss of MSH2 and 
MSH6 on IHC and 100% (n=3) had a MMRD+/VUS in MSH2.  Overall, the majority of the mutations 
for the positive group were truncating mutations (n= 57, 58.8%).  The majority of mutations for the 
MMRD+/VUS group were missense mutations (n= 29, 93.5%).   
Family History Assessments 
Summary statistics for family history scores for both MMRpro and PREMM1,2,6 can be found 
in table 4.  The median family history scores for the LS group were higher on both modalities (MMRpro 
median =89.8; PREMM1,2,6 median =26.1) than the other three groups.  There was a wide range of 
scores for both modalities (MMRpro range=0-100; PREMM1,2,6 range=5.0-97.6, figures 2 and 3).   
PREMM1,2,6 family history scores were lower than MMRpro scores for all groups except sporadic 
MSI-H.  Significant measures between germline groups are summarized in table 5.  Statistical 
significance (alpha = 0.0008) was reached for all comparisons for both MMRpro and PREMM1,2,6 
except for MMRD+/germline- versus MMRD+/VUS (MMRpro p=0.1924; PREMM1,2,6 p=.0249).   
 
 
 
 
 
 
 
  Germline Testing Group N Min Med Max 
 MMRpro  LS 97 0.0 89.8 100.0 
MMRD+/germline- 70 0.0 8.1 100.0 
MMRD+/VUS 31 0.0 28.0 99.8 
sporadic MSI-H 55 0.0 0.7 94.0 
Total 253 0.0 13.9 100.0 
 PREMM1,2,6 LS 97 5.0 26.1 97.6 
MMRD+/germline- 70 5.0 7.3 93.1 
MMRD+/VUS 31 5.0 11.1 82.5 
sporadic MSI-H 55 5.0 5.0 37.4 
  Total 253 5.0 9.2 97.6 
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Figure 2: Median MMRpro Family History Scores 
Figure 3: Median PREMM1,2,6 Family History Scores 
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Family history scores were further stratified by location of cancer, age of diagnosis (<50 versus 
≥50), gender for CRC only, and gene mutated in the LS group only.  Summary statistics for CRC versus 
EC can be found in table 6 and comparison statistics can be found in table 7.  Overall, the LS group had 
family history scores that were higher on both modalities for both CRC (MMRpro median =88.3; 
PREMM1,2,6 median =23.6) and EC (MMRpro median =96.3; PREMM1,2,6 median =36.5) than the 
other three groups.  Statistical significance was reached for CRC sporadic MSI-H versus EC sporadic 
MSI-H on both modalities (MMRpro p=0.0039; PREMM1,2,6 p=0.0016).   EC individuals in the 
sporadic MSI-H group had higher median family history scores (MMRpro median =2.7; PREMM1,2,6 
median=8.7) than CRC individuals in the sporadic MSI-H group (MMRpro median=0.3; PREMM1,2,6 
median=5.0).   
Summary statistics for age of diagnosis can be found in table 8 and comparison statistics can be 
found in table 9.  Overall, the LS group had the highest median family history scores between groups on 
both modalities for diagnosed <50 (MMRpro median =91.7; PREMM1,2,6 median=23.5) and diagnosed 
≥50 (MMRpro median=64.7, PREMM1,2,6 median=30.6) than the other three groups. Statistical 
significance was reached for diagnosed <50 sporadic MSI-H versus diagnosed ≥50 sporadic MSI-H on 
both modalities.  Individuals diagnosed <50 had higher median family history scores (MMRpro  
p-value 
MMRpro <0.0001 
LS vs. MMRD+/germline- <0.0001 
LS vs. MMRD+/VUS 0.0063 
LS vs. sporadic MSI-H <0.0001 
MMRD+/germline-vs. 
MMRD+/VUS 0.1924 
MMRD+/germline-vs. sporadic MSI-H <0.0001 
MMRD+/VUS vs. sporadic MSI-H <0.0001 
PREMM1,2,6 <0.0001 
LS vs. MMRD+/germline- <0.0001 
LS vs. MMRD+/VUS 0.0038 
LS vs. sporadic MSI-H <0.0001 
MMRD+/germline-vs. 
MMRD+/VUS 0.0249 
MMRD+/germline-vs. sporadic MSI-H 0.0013 
MMRD+/VUS vs. sporadic MSI-H <0.0001 
Table 5: Significance of Family History Scores between Germline Groups 
15 
 
median=5.2; PREMM1,2,6 median =7.9) than diagnosed ≥50 (MMRpro median =0.4; PREMM1,2,6 
median =5.0).   
 
 
 
  
 
 
 
 
 
 
 
 
  MMRpro PREMM1,2,6 
 Germline Group N Med Min Max N Med Min Max 
CRC LS 80 88.3 0.0 99.9 80 23.6 5.0 96.0 
 MMRD+/germline- 58 9.7 0.0 100.0 58 7.3 5.0 93.1 
 MMRD+/VUS 28 37.5 0.0 99.8 28 10.9 5.0 82.5 
 sporadic MSI-H 40 0.3 0.0 84.6 40 5.0 5.0 25.1 
EC LS 12 96.3 1.8 100.0 12 36.5 5.0 97.6 
 MMRD+/germline- 12 2.8 0.3 87.3 12 5.7 5.0 45.0 
 MMRD+/VUS 3 20.9 6.1 28.0 3 14.1 8.3 16.7 
 sporadic MSI-H 15 2.7 0.2 94.0 15 8.7 5.0 37.4 
p-value 
MMRpro  
CRC LS vs. EC LS 0.3446 
CRC MMRD+/germline- vs. EC MMRD+/germline- 0.1878 
Colon MMRD+/VUS vs. EC MMRD+/VUS 0.6884 
CRC sporadic MSI-H vs. EC sporadic MSI-H 0.0039 
PREMM1,2,6 
 
CRC LS vs. EC LS 0.3130 
CRC MMRD+/germline- vs. EC MMRD+/germline- 0.6832 
CRC MMRD+/VUS vs. EC  MMRD+/VUS 0.7888 
CRC sporadic MSI-H vs. EC  sporadic MSI-H 0.0016 
    MMRpro PREMM1,2,6 
  Germline Group N Med Min Max N Med Min Max 
Age < 50 LS  53 91.7 1.8 100.0 53 23.5 5.0 97.6 
MMRD+/germline- 32 15.1 0.9 100.0 32 7.3 5.0 91.8 
MMRD+/VUS 18 47.5 0.7 99.8 18 15.6 5.0 82.5 
sporadic MSI-H 11 5.2 0.5 74.2 11 7.9 5.0 25.1 
Age ≥ 50 LS  44 64.7 0.0 100.0 44 30.6 5.0 93.6 
MMRD+/germline- 38 3.4 0.0 100.0 38 7.2 5.0 93.1 
MMRD+/VUS 13 14.8 0.0 88.8 13 9.5 5.0 27.0 
  sporadic MSI-H 44 0.4 0.0 94.0 44 5.0 5.0 37.4 
Table 7: Significance of Family History Scores between Germline Groups and Location of Tumor 
Table 6: Colorectal Cancer versus Endometrial Cancer Summary Statistics 
statistics 
Table 8: Age of Diagnosis Summary Statistics 
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Summary statistics for gender for CRC only can be found in table 10 and comparison statistics 
can be found in table 11.  Overall, individuals in the LS groups had higher median family history scores 
for both modalities for males with CRC (MMRpro median=37.9; PREMM1,2,6 median=23.6) and 
females with CRC (MMRpro median=90.7; PREMM1,2,6 median=21.8) than the other three groups.  
Statistical significance was reached for PREMM1,2,6 for the following comparisons: males 
MMRD+/germline- versus females MMRD+/germline- (p=0.0067) and males sporadic MSI-H versus 
females sporadic MSI-H (p=0.0059).  Males in the MMRD+/germline- group had higher median family 
history scores (median=8.3) than females in the MMRD+/germline- group (median=6.4).  Males in the 
sporadic MSI-H group had higher median family history scores (median =5.5) than females in the 
sporadic MSI-H group (median=5.0).   
 
 
 
 
 
 
p-value 
MMRpro  
< 50 LS vs. ≥ 50 LS 0.0605 
< 50 MMRD+/germline- vs. ≥ 50  MMRD+/germline- 0.0358 
< 50 MMRD+/VUS vs. ≥ 50 MMRD+/VUS 0.0263 
< 50  sporadic MSI-H vs. ≥ 50  sporadic MSI-H 0.0015 
PREMM1,2,6 
 
< 50 LS vs. ≥ 50 LS 0.8933 
< 50  MMRD+/germline- vs. ≥ 50  MMRD+/germline- 0.5646 
< 50 MMRD+/VUS vs. ≥ 50 MMRD+/VUS 0.0370 
< 50  sporadic MSI-H vs. ≥ 50  sporadic MSI-H 0.0072 
    MMRpro PREMM 
  Germline Group N Med Min Max N Med Min Max 
Male LS  47 37.9 0.3 99.8 47 23.6 5.0 96.0 
MMRD+/germline- 28 12.9 0.0 100.0 28 8.3 5.0 93.1 
MMRD+/VUS 18 31.7 0.0 99.8 18 12.3 5.0 82.5 
sporadic MSI-H 13 3.2 0.0 74.2 13 5.5 5.0 25.1 
Female LS 33 90.7 0.0 99.9 33 21.8 5.0 93.6 
MMRD+/germline- 30 9.0 0.0 99.4 30 6.4 5.0 44.2 
MMRD+/VUS 10 40.6 0.6 97.3 10 8.9 5.0 34.5 
  sporadic MSI-H 27 0.3 0.0 84.6 27 5.0 5.0 11.8 
Table 9: Significance of Family History scores between Germline Groups and Age of Diagnosis 
Table 10: Males with Colorectal Cancer versus Females with Colorectal Cancer Summary Statistics 
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Summary statistics for gene mutated in the positive group can be found in table 12.  Individuals 
with MLH1 or MSH2 mutations had significantly higher (p <0.0001) median family history scores on 
both modalities (MMRpro median=95.1; PREMM1,2,6 median=38.7) than individuals with MSH6 or 
PMS2 mutations (MMRpro median=7.7; PREMM1,2,6 median=7.3).   
 
 
 
To establish differences between the LS group and the MMRD+/germline- group, family 
history scores were stratified by gene implicated by germline test result for the LS group and by IHC 
result in the MMRD+/germline- group.  Summary statistics for overall family history scores of the 
MMRD+/germline- group versus MLH1/MSH2 and MSH6/PMS2 mutations in the LS group can be 
found in table 13. Individuals with MLH1 or MSH2 mutations had significantly higher median family 
history scores on both modalities (MMRpro=95.1, PREMM1,2,6=38.7) than the MMRD+/germline- 
group (MMRpro=7.7, p<0.0001; PREMM1,2,6=7.3, p<0.0001).  There was no significant difference 
between individuals with MSH6 and PMS2 mutations and MMRD+/germline- family history scores 
(MMRpro p=0.5933, PREMM1,2,6 p=0.6938).  Summary statistics for gene mutated in the LS group 
versus gene implicated in the MMRD+/germline- group can be found in table 14.  Individuals with an 
Comparison p-value 
MMRpro 
Male LS vs. Female LS 0.2038 
Male MMRD+/germline- vs. Female MMRD+/germline- 0.1556 
Male MMRD+/VUS vs. Female MMRD+/VUS 0.5813 
Male sporadic MSI-H vs. Female sporadic MSI-H 0.0236 
PREMM1,2,6  
Male LS vs. Female LS 0.7066 
Male MMRD+/germline- vs. Female MMRD+/germline- 0.0067 
Male MMRD+/VUS vs. Female MMRD+/VUS 0.2112 
Male sporadic MSI-H vs. Female sporadic MSI-H 0.0059 
  MMRpro** PREMM1,2,6** 
Gene N Med Min Max N Med Min Max 
MLH1/MSH2  71 95.1 0.3 100.0 71 38.7 5.0 97.6 
PMS2/MSH6 25 7.7 0.0 92.1 25 7.3 5.0 65.0 
Table 11: Significance of Family History Scores between Germline Groups and Gender (CRC Only) 
Table 12: Family Histories of Gene Mutated in the LS group Summary Statistics 
** p<0.0001 
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MLH1 mutation had significantly higher family history scores on both modalities (MMRpro=98.4, 
PREMM1,2,6=49.3) than MMRD+/germline- individuals with loss of MLH1/PMS2 on IHC 
(MMRpro=6.9, p<0.0001; PREMM1,2,6=5.6, p<0.0001). 
 
 MMRpro PREMM1,2,6 
Group N Min Med Max p-value N Min Med Max p-value 
MMRD+/germline
- 
142 0.0 7.7 100.0  142 5.0 7.3 93.1  
MLH1/MSH2 
mutations (LS) 
71 0.3 95.1 100.0 <0.0001 71 5.0 38.7 97.6 <0.0001 
MSH6/PMS2 
mutations (LS) 
25 0.0 7.7 92.1 0.5933 25 5.0 7.3 65.0 0.6938 
 
 
    MMRpro PREMM1,2,6 
Group Gene Implicated N Min Med Max p-value N Min Med Max p-value 
LS MLH1  26 4.3 98.4 99.8 <0.0001 26 5.5 49.3 96.0 <0.0001 
MMRD+/ 
germline- MLH1/PMS2 31 0 6.9 87.3   31 5 5.6 45   
LS MSH2  45 0.3 90.8 100.0 0.0812 13 0.1 36.7 100.0 0.0536 
MMRD+/ 
germline- MSH2/MSH6 13 0.1 15.8 100.0   13 5.0 12.1 91.8   
LS MSH6  18 0.3 7.3 91.7 0.9406 18 5.0 8.1 65.0 0.5000 
MMRD+/ 
germline- MSH6 5 0.0 11.1 74.5   5 5.0 7.1 10.5   
LS PMS2  7 0.0 11.4 92.1 0.0527 7 5.0 7.3 23.5 0.0294 
MMRD+/ 
germline- PMS2 3 20.6 96.0 98.1   3 12.6 37.6 75.4   
 
Both family history modalities were significant predictors of testing germline positive in the 
logistic regression analysis.  For every one unit increase in MMRpro, the odds of being germline 
positive increase by a factor of 1.02 (95% CI: 1.01 – 1.03; p < 0.001).  For every one unit increase in 
PREMM1,2,6, the odds of being germline positive increase by a factor of 1.04 (95% CI: 1.02 – 1.05; p 
=  < 0.001).     
 
 
Table 13: MMRD+/germline- versus MLH1/MSH2 mutations and MSH6/PMS2 mutations 
Table 14: LS family history scores versus MMRD+/germline- family history scores 
by gene implicated 
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DISCUSSION 
Demographics and Tumor Characteristics 
 Demographic and tumor characteristics were consistent with what was expected.  Individuals 
with sporadic MSI-H tumors were diagnosed at a later age (60.5 years) than the other three groups, 
consistent with the average age of onset of CRC in the general population (69 years) and the average 
age of onset of EC in the general population (61 years) [26].  Individuals in the LS, MMRD+/germline- 
and MMRD+/VUS groups all had similar mean ages of onset in the 40s.  Average age of CRC diagnosis 
in LS is 42-61 years and average age of EC diagnosis in LS is 47-55 years [27].  A recent study showed 
that individuals with LS and MMRD+/germline- have similar ages of cancer onset [28].   
The MMRD+/VUS group had the most ethnic diversity, as less is known about normal ethnic 
genetic variation outside of the Northern European population.  The preponderance of CRC is easily 
explained by the fact that our institution has only been doing tumor studies on ECs regularly since 
August 2012 and since CRC has a higher incidence (46.3 per 100,000 men and women) than EC (24.1 
per 100,000 women) [26].  Individuals in the LS group were more likely to have additional polyps 
identified at time of diagnosis, which was expected given that these individuals have a diagnosis of LS 
and are therefore at an increased risk for developing polyps that could lead to a CRC.  Individuals in the 
LS group were also more likely to have a stage 1 CRC, consistent with the observation that while these 
individuals are more likely to develop a CRC during their lifetime, these CRCs are typically less 
aggressive and grow more slowly [29].    
With regards to EC, women in the LS group had BMI in the normal range, while the remaining 
3 groups had BMIs in the overweight range.  Obesity is a known risk factor for sporadic EC.  The 
preponderance of MSH2 mutations in the study population is consistent with the American population, 
which has a higher rate of MSH2 germline mutations in LS [30].  
Family History Assessments and Comparisons 
 The results of this study indicate that individuals with LS have more suggestive family histories 
than individuals with MMRD+/germline-, suggesting that perhaps individuals with MMRD+/germline- 
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do not truly have LS.  We expect individuals with a hereditary cancer syndrome such as LS to, in 
general, have a family history of related cancers.  When the family history is less impressive, our 
concern for a hereditary cancer syndrome is decreased.  Because individuals with MMRD+/germline- 
have less impressive family histories, the suspicion for a hereditary predisposition to cancer decreases.  
Individuals with MMRD+/germline-, however, do have more suggestive family histories than 
individuals with a sporadic MSI-H tumor.  This indicates that individuals with MMDR+/Lynch- have 
higher incidence of LS-related tumors in their families.  Interestingly, individuals with a MMRD+/VUS 
identified have similar family histories to individuals with MMRD+/germline-.  There are a number of 
possible explanations for this: the MMRD+/VUS group could be a mix of pathogenic and non-
pathogenic mutations, individuals may have an undetectable pathogenic mutation, or having a 
MMRD+/VUS could indicate an increased cancer risk over the general population, based on the 
suggestive family histories.  On the spectrum of family histories, individuals with LS have the most 
suggestive family histories, individuals with sporadic MSI-H tumors have the least suggestive family 
histories and individuals with MMRD+/germline- or a MMRD+/VUS have family histories in the 
middle.   
 The results of this study are intriguing.  The hypothesis was confirmed and we have 
demonstrated that the MMRD+/germline- individuals lie in the middle of the family history spectrum.  
These results are consistent with a recent population-based study by Rodriguez-Soler and colleagues 
[28], who determined that the families of individuals with MMRD tumors but no identifiable germline 
mutation have a lesser risk of developing colorectal cancer in their lifetime than LS families, but a 
higher risk than individuals with a known sporadic tumor.  Families of individuals with MMRD tumors 
but no identifiable germline mutation also had less family history of LS-related tumors.  In fact, 50% of 
these individuals were the index case of cancer in their family [28].   
 Possible explanations as to why the MMRD+/germline- population fall in the middle of the 
family history spectrum include the following.  The cohort could be a mixture of individuals with true 
LS, whom our current genetic testing technology is not sensitive enough to detect their mutation, and 
individuals who do not have LS, but rather have an MMRD sporadic tumor.  It is also possible that this 
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cohort represents a currently undefined hereditary cancer syndrome or subset of LS, with lower cancer 
risks than true LS, but increased risks over the general population.   
 As expected, individuals with an MLH1 or MSH2 mutation had significantly higher median 
family history scores than individuals with an MSH6 or PMS2 mutations.  Lifetime CRC and EC cancer 
risks for individuals with an MSH6 or PMS2 mutation are lower than the risks associated with MLH1 
and MSH2 mutations.  Males and females with an MSH6 mutation have a 44% and a 20% lifetime risk 
of developing colorectal cancer respectively [23].  Individuals with a PMS2 mutation have a lifetime 
risk of 15-20% for CRC [17].  Women with a PMS2 mutation have a 15% lifetime risk for EC [17].   
 It appears that the differences between the family history scores are driven by the family history 
scores of individuals with an MLH1 or an MSH2 mutation.  Family history scores of MMRD+/germline- 
individuals were more similar to family history scores of individuals with an MSH6 or a PMS2 
mutation.  This could indicate that the cancer risks for MMDR+/germline- individuals are more similar 
to those of individuals with an MSH6 or a PMS2 mutation, as shown by Rodriguez-Soler and colleagues 
[28].  It could also indicate that some individuals in the MMRD+/germline- group may have MMRD 
tumors due to a low penetrant germline mutation in a currently unidentified cancer predisposition gene.   
 Both MMRpro and PREMM1,2,6 scores were positively correlated with the odds of testing 
germline positive.  These results indicate that family history is still an important piece of information in 
the clinical assessment.  While universal tumor screening protocols are certainly more effective than 
other previously used protocols, there is the potential for family history to be overlooked.  Even for 
individuals who have an MMRD tumor, family history should still play a vital role in their risk 
assessment.  As universal tumor screening protocols become more widespread, we will likely identify 
just as many individuals in the MMRD+/germline- group as the LS group.    
 The other statistically significant comparisons can be explained by the differences in the models 
previously observed in other studies.  MMRpro scores tend to be higher than PREMM1,2,6 scores, 
likely due to the fact that MMRpro can take into account more family history information than 
PREMM1,2,6 [31]  Neither of the models have proven to be effective at predicting germline mutation 
status in EC, as both overestimate the likelihood [32].  Because both models place weight on the age of 
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diagnosis in the risk assessment, it is not unexpected that a young age of diagnosis increases the family 
history score.  These results validate that the models were functioning as expected in our study 
population, indicating that the study design was sound.   
Implications and Future Directions 
 The results of this study and the population-based study by Rodriguez-Soler and colleagues [28] 
confirm the need for continued research into the causes of MMRD tumors, including sporadic, 
epigenetic and germline causes.  In the recent months, there has been increasing research into other 
possible sporadic causes of MMRD tumors [15, 21, 22].  At this time, however, the only clinically 
available testing for sporadic causes of MMRD tumors is MLH1 hypermethylation and BRAF V600E 
mutation analysis.  Many of the recently discovered somatic and epigenetic causes of MMRD tumors 
were found through sequencing of the tumor genome.  There may be a need to further explore the utility 
of sequencing tumor genome in the clinical setting, especially in cases of MMRD+/germline-.  It is also 
quite possible that there are other germline causes of MMRD tumors outside of MLH1, MSH2, MSH6, 
PMS2.  There could be other modifier genes that act in a similar fashion to EPCAM/TACSTD1, that 
remain to be discovered.  Deletions in EPCAM/TACSTD1 cause heritable epigenetic silencing of MSH2 
[33].  There are also a number of other MMR genes outside of those already implicated in LS that could 
be further explored, such as MSH3 and MLH3 [34].   
 The need to reassess the clinical management of individuals with MMRD+/germline- also needs 
to be addressed.  At this time, we recommend that individuals with MMRD+/germline- follow the same 
screening guidelines as individuals with LS because no clinical tools exist yet to distinguish LS and 
MMRD+/germline-.  This includes: colonoscopy annually beginning at age 20-25 and upper endoscopy 
every 3-5 years beginning at age 30-35 for males and females, and endometrial biopsy annually for 
females [35].  While there is clear clinical benefit to colonoscopy, there has been no proven clinical 
benefit for upper endoscopy, or endometrial biopsy.  In fact, the most effective way to prevent 
endometrial cancer is to undergo a total abdominal hysterectomy after childbearing is completed [35].  It 
is extremely difficult, however, to make such drastic surgical recommendations to individuals with 
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MMRD+/germline- and their families, as we are unsure if they truly have LS.  While colonoscopy is 
quite effective at preventing colorectal cancer, it does not come without risks, including perforation 
(0.04% risk), post-polypectomy hemorrhage (0.26% risk) and adverse reactions to sedation/anesthesia 
[36].  If an individual with LS is found to have a CRC, there is often a discussion regarding performing 
more radical colon surgery than simply removing the affected area [35].  As with a prophylactic 
hysterectomy, these conversations are difficult to have with an MMRD+/germline- individual.  
 If individuals with MMRD+/germline- do not truly have LS, and have lower colorectal cancer 
risks as suggested by Rodriguez-Soler and colleagues [28], then they likely do not need to be 
undergoing invasive screening as often as individuals with LS.  They do, however, need increased 
screening in comparison to the general population.  As previously stated, the age of onset for cancer in 
our MMRD+/germline- population is similar to that of the LS population (51.3 years and 48.3 years, 
respectively), which is consistent with the results of the Rodriguez-Soler et al. study [28].   Based on 
this, it seems appropriate to beginning surveillance at a younger age.  But the question of exactly how to 
screen MMRD+/germline- individuals and their families remains.  As stated by Rodriguez-Soler and 
colleagues, we as a medical community must strike a balance in screening MMRD+/germline- 
individuals [28].  It would be inappropriate to follow these individuals with general population 
screening recommendations based on the increased cancer risks and increased family history of cancer, 
as we could begin missing preventable cancers.  It is also likely inappropriate to be subjecting these 
individuals to increased surveillance when they do not appear to have the same cancer risks as 
individuals and families with LS [28].  Further work needs to be done to further define the CRC and 
extra-colonic cancer risks in MMRD+/germline- individuals to develop appropriate surveillance 
recommendations.   
Strengths and Limitations 
 There are a number of strengths to this study.  Firstly, we have a large cohort of individuals who 
all underwent genetic counseling, tumor studies, genetic testing and had pedigrees available for analysis.  
Secondly, we included both endometrial and colorectal cancer.  Thirdly, we included the MMRD+/VUS 
group in our analyses.   
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 The limitations to this study are as follows.  MMRpro and PREMM1,2,6 each have their own 
set of limitations.  Clinical judgment is often the best form of pedigree assessment, but can be 
subjective.  MMRpro and PREMM1,2,6 provided a way to quantify family histories, but may have been 
an over- or under-estimate, based on the formulation for risk assessment for the respective risk models.  
The limitations of these models were present for all groups, thus there was still a valid comparison.  The 
pedigrees themselves may pose a limitation, as they rely on the patient as the historian and the genetic 
counselor as an accurate scribe.  The family history of LS can also be variable.  This was confirmed in 
our comparison of the family history scores of MLH1/MSH2 and MSH6/PMS2.  While this could be 
viewed as a limitation, in actuality, our study indicates that all individuals with LS, regardless of which 
MMR gene is mutated, have more suggestive family histories.  There were a number of individuals in 
the MMRD+/germline- group who were lost to follow up or who were deceased before a complete 
genetic work-up could be completed.  It is possible that some of these individuals truly had LS or truly 
had a sporadic MSI-H tumor, but the appropriate testing was never performed.  Despite this, the 
MMRD+/germline- group still had less suggestive family histories than the LS group.  Some individuals 
had missing demographic and medical history information, which was not actively sought.  Only CRC 
or EC cancers with tumor studies were included in analysis.  There were other females in our cohort that 
had both CRC and EC, but only had tumor testing performed on one tissue.  Finally, the cohort was 
taken from one institution.   
Because this was not a population-based study, there is the potential for referral bias.  For 
colorectal cancers diagnosed or treated prior to 2009, the practice at MD Anderson Cancer Center was 
to perform tumor studies on and/or provide a genetics referral only for individuals at a “high risk”.  This 
included: right-sided tumors, diagnosed younger than 50 years old, or a suggestive family history.  All 
of these factors are incorporated into the risk models, resulting in an increased risk assessment for 
finding a germline MMR mutation. After 2009, MD Anderson Cancer Center adopted a more universal 
tumor studies approach for colorectal cancers.  Tumor studies for endometrial cancer, however, have 
only routinely been performed at MDACC since August 2012.  Regardless of this potential bias, 
MMRD+/germline- individuals referred still had less suggestive family histories than LS individuals.  It 
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is possible that the schism between family history scores for MMRD+/germline- and LS could be more 
pronounced in the general population.  
Conclusion 
In conclusion, individuals with MMRD+/germline- have a less suggestive family history than 
individuals with LS, but a more suggestive family history than individuals with a sporadic MSI-H tumor 
and a similar family history to individuals with a MMRD+/VUS.  These results further reinforce the 
need to continue exploring other causes of MMRD tumors, as it does not all appear to be LS.  As our 
understanding of other somatic and epigenetic causes of MMRD tumors expands, we need to reevaluate 
our current testing practices and develop other clinical testing to rule out all known somatic and 
epigenetic causes.  We also need to reconsider the current screening guidelines for individuals with 
MMRD+/germline-, as we may be subjecting these individuals to unnecessary invasive surveillance.   
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